Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 4/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178560 | 0.86 | RARB (0.67) | TSHRRECQLRARBRARGITGB3 | |
| SCHEMBL8533567 | 0.82 | RARB (0.71) | TSHRRARBALDH1A1MAPTNPC1 | |
| SCHEMBL8181561 | 0.82 | RARB (0.71) | TSHRRARBALDH1A1MAPTNPC1 | |
| SCHEMBL5351127 | 0.82 | RARB (0.71) | TSHRRARBALDH1A1MAPTNPC1 | |
| SCHEMBL13527301 | 0.81 | RARB (0.68) | TSHRRARBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7342399 | 0.80 | KCNH2 (0.67) | KMT2ATSHRRARBMAPTNPC1 | |
| SCHEMBL15060975 | 0.80 | KCNH2 (0.67) | KMT2ATSHRRARBMAPTNPC1 | |
| SCHEMBL7195953 | 0.79 | TSHR (0.63) | KMT2ATSHRRECQLALDH1A1ITGB3 | |
| SCHEMBL7195903 | 0.79 | TSHR (0.63) | KMT2ATSHRRECQLALDH1A1ITGB3 | |
| SCHEMBL10599988 | 0.78 | RECQL (0.77) | KMT2ATSHRRECQLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | KMT2A 2499/4885TSHR 358/4885RECQL 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.